Inclusion Criteria:  Male or female, 59 > =Age (years) >= 18; Newly diagnosed as AML patients according to World Health Organization (WHO) classification; Patients have not received prior therapy for AML (except hydroxyurea and Ara-C<1.0g/d); Eastern Cooperative Oncology Group (ECOG) Performance status of 0,1, 2 ; Liver function: Total bilirubin ≦3 upper limit of normal (ULN); aspartate aminotransferase (AST) ≦3 ULN; alanine aminotransferase (ALT)≦3 ULN(except extramedullary infiltration of leukemia) Renal function：Ccr（Creatinine Clearance Rate） ≧30 ml/min; Patients who sign the informed consent must have the ability to understand and be willing to participate in the study and sign the informed consent.  Exclusion Criteria:  Acute promyeloid leukemia； AML with central nervous system (CNS) infiltration； Patients have received prior hypomethylating agents (HMA) therapy for myelodysplastic syndrome (MDS) and progressed to AML； HIV infection; Patients with severe heart failure (grade 3-4) ; Evidence of other clinically significant uncontrolled condition(s) including, but not limited to: a) Uncontrolled and/or active systemic infection (viral, bacterial or fungal); b) Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. c) An active second cancer that requires treatment within 6 months of study entry Patients deemed unsuitable for enrolment by the investigator; Patients willing to receive intensive induction chemotherapy Female who are pregnant, breast feeding or childbearing potential without a negative urine pregnancy test at screen； Patients reject to participate in the study.